NASDAQ : ARQT
Arcutis Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 32.07 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.03B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.03B |
| Enterprise Value | 3.91B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 125.69M |
| Shares Outstanding | 125.69M |
| Shares Change (YoY) | +5.07% |
| Shares Change (QoQ) | +5.05% |
| Owned by Insiders (%) | 1.03% |
| Owned by Institutions (%) | 89.67% |
| Float | 93.82M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 148.88 |
| Forward PE | 47.39 |
| PS Ratio | 8.69 |
| Forward PS | 6.67 |
| PB Ratio | 18.26 |
| P/TBV Ratio | 19.48 |
| P/FCF Ratio | 102.96 |
| P/OCF Ratio | 102.54 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 136.98 |
| EV / Sales | 8.42 |
| EV / EBITDA | 107.02 |
| EV / EBIT | 114.05 |
| EV / FCF | 99.78 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.92 |
| Quick Ratio | 2.46 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 3.06 |
| Debt / FCF | 2.92 |
| Interest Coverage | 2.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 15.86% |
| Return on Assets (ROA) | 5.09% |
| Return on Invested Capital (ROIC) | 37.79% |
| Return on Capital Employed (ROCE) | 10.44% |
| Weighted Average Cost of Capital (WACC) | 13.19% |
| Revenue Per Employee | $1.31M |
| Profits Per Employee | $80,562 |
| Employee Count | 354 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 1.49 |
Taxes
| Measure | Value |
|---|
| Income Tax | 779,000 |
| Effective Tax Rate | 2.66% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.63 |
| 52-Week Price Change | +26.81% |
| 50-Day Moving Average | 26.66 |
| 200-Day Moving Average | 25.25 |
| Relative Strength Index (RSI) | 66.34 |
| Average Volume (20 Days) | 2,341,042 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.49M |
| Short Previous Month | 21.69M |
| Short % of Shares Out | 16.30% |
| Short % of Float | 21.84% |
| Short Ratio (days to cover) | 6.13 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 463.98M |
| Gross Profit | 422.89M |
| Operating Income | 34.25M |
| Pretax Income | 29.30M |
| Net Income | 28.52M |
| EBITDA | 36.50M |
| EBIT | 34.25M |
| Earnings Per Share (EPS) | $0.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 238.55M |
| Total Debt | 114.14M |
| Net Cash | 124.42M |
| Net Cash Per Share | $0.99 |
| Equity (Book Value) | 220.58M |
| Book Value Per Share | 1.76 |
| Working Capital | 307.33M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 39.31M |
| Capital Expenditures | -158,000 |
| Depreciation & Amortization | 2.25M |
| Net Borrowing | n/a |
| Free Cash Flow | 39.15M |
| FCF Per Share | $0.31 |
Margins
| Measure | Value |
|---|
| Gross Margin | 91.14% |
| Operating Margin | 7.38% |
| Pretax Margin | 6.31% |
| Profit Margin | 6.15% |
| EBITDA Margin | 7.87% |
| EBIT Margin | 7.38% |
| FCF Margin | 8.44% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.07% |
| Shareholder Yield | n/a |
| Earnings Yield | 0.67% |
| FCF Yield | 0.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.13 |
| Price Target Difference | 22.01% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 31.02% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 4.86 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |